肠促胰素受体激动、去脂体重与心肺适能:一项叙述性综述
本叙述性综述讨论肥胖人群心肺适能(CRF)低下的机制,以及GLP-1受体激动剂(GLP-1RA)和GLP-1/GIP双受体激动剂(GLP-1/GIPRA)对去脂体重(FFM)与CRF的影响。文中指出,GLP-1RA及双受体激动剂所致减重中约25%至40%来自FFM丢失,远超成人随年龄增长的年度FFM下降速度;临床研究未显示CRF改善。结论认为,需进一步研究肠促胰素受体激动、FFM、心血管直接指标与CRF决定因素之间的相互作用。
要点
- 肥胖人群常见CRF低下,CRF是全因死亡和心血管死亡的独立预测因素。
- GLP-1RA与双GLP-1/GIPRA减重中约25%至40%来自FFM丢失,超过成人年龄相关的年度FFM下降。
- 临床研究未显示CRF改善,FFM丢失的长期影响仍不明确。
核心结论
- GLP-1RA与双GLP-1/GIPRA显著降低体重和脂肪量,同时伴显著FFM丢失,但无明确证据显示CRF改善。
- 需进一步研究以阐明GLP-1与双GLP-1/GIP受体激动、FFM、心血管直接测量指标及CRF决定因素之间的复杂相互作用,以优化肥胖和2型糖尿病的临床结局。
研究设计与样本
- 本文为叙述性综述,围绕肥胖、肠促胰素受体激动、FFM与CRF的相关证据进行描述。
主要发现
- 肥胖人群常伴低CRF,CRF由Fick原理定义,即心输出量与外周氧摄取的乘积。
- 心血管功能障碍与肌肉质量下降(脂质浸润、肌肉量相对较低、微血管功能障碍)共同影响Fick方程的决定因素,导致该人群CRF低下。
- 减重干预(包括GLP-1RA与双GLP-1/GIPRA)可能改善这些指标,但近期试验显示GLP-1RA与双GLP-1/GIPRA治疗加速FFM丢失。
- 证据表明,GLP-1RA与双GLP-1/GIPRA所致减重中约25%至40%来自FFM丢失,远超成人随年龄增长的年度FFM下降速度。
- 这些治疗在伴或不伴2型糖尿病者中诱导显著减重、降低血糖并显示心血管获益,但临床研究未能显示CRF改善,FFM丢失的长期影响仍未知。
关键数值与推荐
- 原文报告GLP-1RA与双GLP-1/GIPRA所致减重中约25%至40%来自FFM丢失。
- 原文将CRF定义为Fick原理的产物,即心输出量与外周氧摄取的乘积。
- 原文指出FFM丢失速率远超成人随年龄增长的年度FFM下降速度,原文未给出具体数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Individuals with obesity often exhibit low muscle quality and are at risk of reduced muscle mass and diminished cardiorespiratory fitness (CRF). Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIPRA) promote significant loss in adipose tissue but are also associated with notable reductions in fat-free mass (FFM). It is not yet understood how these drugs affect CRF, which is an independent predictor of all-cause and cardiovascular mortality. EVIDENCE DESCRIPTION: People with obesity frequently have low CRF, which is defined by the Fick principle-the product of cardiac output and peripheral oxygen extraction. Cardiovascular dysfunction and reduced muscle quality, due to lipid infiltration, relatively low muscle mass, and dysfunctional microvasculature, work in concert to affect the determinants of the Fick equation and cause low CRF in this population. Weight loss interventions, including GLP-1RAs and dual GLP-1/GIPRA, may improve these measures. However, recent trials show GLP-1RAs and dual GLP-1/GIPRA therapy accelerates FFM loss. Evidence indicates that approximately 25% to 40% of weight loss attributed to GLP-1RAs and dual GLP-1/GIPRA comes from FFM loss, a rate far exceeding the annual age-related decline of FFM in adults. While these therapies have revolutionized obesity and glycemic management by inducing significant weight loss, reducing blood glucose levels, and demonstrating cardiovascular benefits in individuals with or without type 2 diabetes, clinical studies have failed to show improvements in CRF, a critical determinant of long-term cardiovascular health, and the long-term implications of FFM loss in these individuals remain unknown. CONCLUSION: GLP-1RAs and dual GLP-1/GIPRA significantly reduce body weight and adiposity, along with a substantial FFM loss but with no clear evidence of CRF enhancement. Further research is needed to elucidate the complex interplay among GLP-1 and dual GLP-1/GIP receptor agonism, FFM, direct cardiovascular measures, and determinants of CRF to optimize clinical outcomes in obesity and type 2 diabetes.
引用
- Liu Z, Weeldreyer NR, Angadi SS, et al. Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review. J Clin Endocrinol Metab. 2025. PMID: 40488294. doi:10.1210/clinem/dgaf335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。